SPOTLIGHT INNOVATION LECTURE: The CEP Paradox: Reconciling Clinical Evidence, Patient’s Expectations and Future Technological Developments
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Equity/Stock(s)/Options - Filterlex; Trisol; Intratech; Vectorious; Microbot
- Consultant Fee/Honoraria/Speaker's Bureau - Megenta